Challenges in Managing Progressive Multiple Sclerosis

Slides:



Advertisements
Similar presentations
Remyelination Therapy for Multiple Sclerosis By Jordan Burnett With Dr. Gullo clerosis.jpg.
Advertisements

Upfront Combination Therapy vs Step-Up Approach for PAH:
Applying the New Multiple Sclerosis Guidelines to Clinical Practice
Multiple sclerosis: Oral Therapies and Beyond
Immune Depletion, Immune Modulation, and Immunosuppression in MS: A Review.
Engaging the INSULIN-TREATED T2DM Patient: the Importance of Real-World Data.
IL-12 and IL-23.
Highlights From the 2015 European Multiple Sclerosis Meeting
Optimizing Statin Therapy
Statin Selection Aimed to Reduce New-Onset DM Risk:
Glaucoma Progression.
Discussion Outline Cells of the Immune System.
Nat. Rev. Neurol. doi: /nrneurol
What Predicts Disability Progression in Multiple Sclerosis?
Current Controversies in Multiple Sclerosis Management
New Challenges Facing Multiple Sclerosis Nurses
Emerging Data and Clinical Advances in MS:
Insulin Innovation.
Cancer Stem Cell Therapies in Gastrointestinal Cancers
American Heart Association Scientific Sessions
Goals of Therapy in Relapsed CLL
What Do Primary Care Physicians Need to Know About Insulin/GLP-1 RA Fixed-Ratio Combinations?
Innovative Insulin Combinations: A New strategy for the Person With T2DM.
Beyond Statin Therapy.
Goals. The Truth About Statins: High vs Moderate Dose for Secondary Prevention of CAD.
Statins and New-Onset Diabetes REAL Updates and Clinical Implications
Assessing Disease Progression in MS Treatment
Assessing the State of Statin Therapy
Are We Closer to Personalized Medicine in MS?
Updates in Lymphoma From Recent Congresses
The future of urate-lowering strategies for gout
Case Collection in RA: Highlights of an Interactive Workshop
The Biology Behind BCL2 as a Target in Myeloma
What Is the Role of Injectables in the Modern Era of MS Treatment?
EHL Technologies in Hemophilia Care
Insulin Innovation.
Program Goals Overview Glatiramer Acetate 3 Times a Week.
Advancing the Treatment of IBD With Biologics
What's New on Interventions for Lower Limb Spasticity?
Treating CD30-Expressing Cutaneous T-Cell Lymphoma
Program Goals Overview Is NEDA a Reasonable Target?
Novel Insulin/GLP-1 Combinations: Of Interest to the Primary Care Physician?
Optimizing Insulin Therapy in Primary Care: Basal Plus Incretin Combinations.
Clinical Pearls on Hot Topics in MS
Program Goals Disclaimers Defining Refractory Seizures.
Breaking News in Pemphigus Vulgaris and the Latest Updates for Your Practice.
Managing Patients with Relapsed CLL who Discontinue BCR Signaling Inhibitors.
Are We Making Progress in the Management of Huntington Disease?
PEARLS OF WISDOM WITH COMBINATION THERAPY IN PAH
Glucose Management and Statin Therapy
Goals. The Truth About Statins: High vs Moderate Dose for Secondary Prevention of CAD.
Emerging Multiple Sclerosis Therapies
Improving Outcomes in Patients With SSc-ILD
Clinical Challenges and Updates in Managing Seizure Clusters
Program Goal. Program Goal Disclaimer Overview.
Secondary Progressive Multiple Sclerosis: What Do We Know and Where Are We Heading?
Program Goals Overview Is NEDA a Reasonable Target?
Navigating New Treatment Landscapes in HR+ HER2-Negative Advanced Breast Cancer.
Novel Therapeutics in MS
Breaking Barriers in PAH: Role of Novel Early Treatment Strategies
Optimizing Outcomes for Patients With Systemic Lupus Erythematosus: Key Considerations.
Clinical Challenges in the Patient With Relapsed Multiple Myeloma
Glucose Management and Statin Therapy
PAH Pathways: What Do the Data Tell Us?”
Introduction. Welcome to this program, titled De-Escalating Therapy in Epilepsy: A Return to Monotherapy.
Statin Selection in Patients With Pre-Diabetes: Case Considerations
MS, Age, and Immune Function
Updates in Progressive MS
What's New in Rare CKDs?.
Fresh perspectives ON BASAL Insulins in diabetes care
Presentation transcript:

Challenges in Managing Progressive Multiple Sclerosis

Program Goals

Disclaimers

Overview

Progressive MS Onset, Mechanisms

Inflammation: A Target in Progressive MS?

Inflammation as a Target in Progressive MS: Therapeutic Lag?

PPMS Trials: Too Short or Too Late? UCSF Experience

Predicting Progression

Prognostic Profiling Possible Clinical Trial End Points

Clinical Trials in Progressive MS

Is There a Role for Rituximab? UCSF Experience

Is There a Role for Statins?

INFORMS -- What Did We Learn?

INFORMS -- What Did We Learn? (cont)

Laquinimod

B-Cell Therapies

Triamcinolone

Combination Therapy and Remyelination

Remyelination

Phenytoin in Optic Neuritis Proof-of-Concept Trial

Biotin in SPMS

Summary and Key Points

Abbreviations

Abbreviations (cont)

References

References (cont)

References (cont)

References (cont)

References (cont)

References (cont)